“Our work with Olink on plasma-based immuno-oncology (IO) applications has allowed the identification of tumor and immune changes associated with immune checkpoint inhibitor response/non-response.This is particularly exciting as we combine this technology with deep tumor-based analysis to understand tumor-immune interactions and establish predictive and/or monitoring tools for IO. The small volume required for Olink analysis is a game-changer as it allows multi-analyte assessment of samples and validation of findings by multiple orthogonal platforms.”
Genevieve M. Boland, Director Melanoma Surgery Program, Massachusetts General Hospital, Boston
“My interest in biomarkers grew in parallel to the growth of Olink. Back in 2014, when I first selected the Olink technology for an important EU-funded program that I was coordinating, the company had only a handful of employees. Since then, Olink’s growth was amazing. Yet, they still behave like partners, not simple providers. I have since recommended Olink to many international colleagues”
Faiez Zannad, Professeur de Thérapeutique-Cardiologie Coordinateur, Centre d’Investigation Clinique Inserm, CHU, Université de Lorraine
“We have employed Olink panels in longitudinal deep phenotyping studies of over 5,000 individuals. We have found the data quality and reproducibility to be among the best of the high dimensional data strategies we have used.”
Professor Leroy Hood, Institute for Systems Biology, Seattle WA.
“Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.”
Professor C.Thomas Caskey, Baylor College of Medicine, Houston TX.
“I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains”
Professor Tomas Olsson, Center for Molecular Medicine, Karolinska Hospital, Stockholm.
“Very impressive in turnaround time for analysis, guidance in interpretation of results, and support involving subsequent queries. The best company we have dealt with in 2017!”
Professor H. Denis Alexander, University of Ulster, Northern Ireland
“Analysis of changes in the profile of protein inflammation biomarkers using the Olink panels opens up a new window of knowledge”
Professor Magnus Grenegård, School of Medical Sciences, Örebro University.
“The Olink CVD panels have given us a great opportunity to search for new proteins linked to cardiovascular disease”
Professor Lars Lind, Department of Medical Sciences, Uppsala University.
“In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma”
Assistant Professor Petter Brodin, Department of Medicine, Karolinska Institute, Stockholm.
“Through the Olink inflammation panel, we gained knowledge about novel inflammatory pathways in the autoimmune neuromuscular disorder myasthenia gravis. These data bring us one step closer to finding protein biomarkers in different subgroups of this chronic disorder.”
Associate professor Anna Rostedt Punga, Department of Neuroscience, Uppsala University.
“We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.”
Professor Mathias Uhlen, Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm.
“The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers”
Tom Lanz, Principal Scientist, Pfizer Neuroscience
“Proteomics underpins high-resolution analysis of complex biological systems and pathological processes. This information is increasingly applied to translational medicine to improve patient outcomes and address the economic prerogatives of health care systems. It is critical that scientists have a proteomics service that is based on reliable analytical systems, provides effective data management and delivers expert post-analysis technical support. I am happy to say that Olink Proteomics emphatically delivers all these elements”
Dr John Taylor, Centre for Oral Health Research, Newcastle University
“Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)”
Professor Mike Snyder, Department of Genetics, Stanford University
“Olink’s 92-plex Immuno-Oncology panel offers a unique compilation of molecules that play key roles in immunotherapeutic treatments. Miniaturization of the assay to use only 1 µL of sample is a significant advantage for clinical studies with limited amounts of biospecimens”
Assistant Professor Seunghee Kim-Schulze, Hess Center for Science and Medicine, Human Immune Monitoring Core Facility (HIMC), Mount Sinai School of Medicine New York.
“Olink’s multiplex immunoassay panels are unique tools for finding new biomarkers and gaining a better understanding of the pathophysiology of diseases, which is something I apply in my own field of pain research.”
Professor Torsten Gordh, Department of Surgical Sciences, Uppsala University
“Protein signatures can improve our understanding of pathophysiology and disease progression, to better predict clinical outcomes and tailor treatments to match individual patient needs. Olink‘s panels require such a small volume of material that it is now possible to analyze temporal profiles of multiple biomarkers of complex disease processes that would be very difficult to examine with other techniques.”
Professor Lars Hillered, Department of Neuroscience, Uppsala University